Discover
DNA
Ginkgo Bioworks Holdings, Inc.
13.00
500 x 12.86
100 x 13.15
bid
ask
+
1.66
14.64%
300 @ 07:39 PM
13.02 +0.02 (0.15%)
| Ytd | 56.44% | |
| 1y | -14.70% |
11.48
day range
13.55
5.48
52 week range
15.83
| Open | 11.76 | Prev Close | 11.34 | Low | 11.48 | High | 13.55 | Mkt Cap | 875.42M |
| Vol | 4.52M | Avg Vol | 1.80M | EPS | -5.80 | P/E | N/A | Forward P/E | -5.17 |
| Beta | 1.79 | Short Ratio | 6.35 | Inst. Own | 73.73% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 8.48 | 200-d Avg | 8.41 | 1yr Est | 7.00 |
| Income Statement | |||
| Total Revenue | 20.16M | ||
| Revenues (USD) | 20.16M | ||
| Cost of Revenue | 1.72M | ||
| Gross Profit | 18.44M | ||
| Operating Expenses | 76.99M | ||
| Research and Development Expense | 46.21M | ||
| Selling, General and Administrative Expense | 30.78M | ||
| Operating Income | -58.55M | ||
| Income Tax Expense | 128.00K | ||
| Net Income | -46.71M | ||
| Net Income Common Stock | -46.71M | ||
| Net Income Common Stock (USD) | -46.71M | ||
| Consolidated Income | -46.71M | ||
| Net Income from Discontinued Operations | -10.61M | ||
| Earnings per Basic Share | -0.75 | ||
| Earnings per Basic Share (USD) | -0.75 | ||
| Earnings per Diluted Share | -0.75 | ||
| Earning Before Interest & Taxes (EBIT) | -46.58M | ||
| Earning Before Interest & Taxes (USD) | -46.58M | ||
| Weighted Average Shares | 62.09M | ||
| Weighted Average Shares Diluted | 62.09M | ||
| Balance Sheet | |||
| Cash and Equivalents | 169.10M | ||
| Cash and Equivalents (USD) | 169.10M | ||
| Investments | 240.02M | ||
| Investments Current | 217.63M | ||
| Investments Non-Current | 22.39M | ||
| Trade and Non-Trade Receivables | 13.01M | ||
| Current Assets | 332.54M | ||
| Property, Plant & Equipment Net | 504.85M | ||
| Total Assets | 990.05M | ||
| Total Debt | 404.11M | ||
| Current Liabilities | 72.74M | ||
| Debt Non-Current | 404.11M | ||
| Total Liabilities | 569.76M | ||
| Accumulated Retained Earnings (Deficit) | -6.28B | ||
| Accumulated Other Comprehensive Income | 950.00K | ||
| Shareholders Equity | 420.28M | ||
| Shareholders Equity (USD) | 420.28M | ||
| Assets Non-Current | 657.51M | ||
| Total Debt (USD) | 404.11M | ||
| Deferred Revenue | 89.75M | ||
| Goodwill and Intangible Assets | 44.39M | ||
| Liabilities Non-Current | 497.02M | ||
| Trade and Non-Trade Payables | 9.57M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 18.46M | ||
| Net Cash Flow from Financing | 16.49M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -16.65M | ||
| Capital Expenditure | -2.62M | ||
| Issuance (Purchase) of Equity Shares | 17.05M | ||
| Net Cash Flow from Investing | 11.09M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 13.71M | ||
| Net Cash Flow from Operations | -44.27M | ||
| Effect of Exchange Rate Changes on Cash | 43.00K | ||
| Share Based Compensation | 7.60M | ||